CN102551065B - Blood sugar reducing food series - Google Patents
Blood sugar reducing food series Download PDFInfo
- Publication number
- CN102551065B CN102551065B CN2012100716370A CN201210071637A CN102551065B CN 102551065 B CN102551065 B CN 102551065B CN 2012100716370 A CN2012100716370 A CN 2012100716370A CN 201210071637 A CN201210071637 A CN 201210071637A CN 102551065 B CN102551065 B CN 102551065B
- Authority
- CN
- China
- Prior art keywords
- powder
- blood sugar
- boundless
- cyperus
- indistinct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004369 blood Anatomy 0.000 title abstract description 46
- 239000008280 blood Substances 0.000 title abstract description 46
- 235000013305 food Nutrition 0.000 title abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 34
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 241000234653 Cyperus Species 0.000 claims description 50
- 238000001035 drying Methods 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 10
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 244000241838 Lycium barbarum Species 0.000 claims description 7
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 7
- 235000012907 honey Nutrition 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 239000007788 liquid Substances 0.000 abstract description 19
- 239000006187 pill Substances 0.000 abstract description 13
- 239000003826 tablet Substances 0.000 abstract description 11
- 244000046052 Phaseolus vulgaris Species 0.000 abstract description 7
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract description 7
- 239000007910 chewable tablet Substances 0.000 abstract description 7
- 241000689272 Senna sophera Species 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 5
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 230000036772 blood pressure Effects 0.000 abstract description 4
- 235000015895 biscuits Nutrition 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 201000001421 hyperglycemia Diseases 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 239000000284 extract Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229940023488 pill Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 240000006079 Schisandra chinensis Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000002722 Dioscorea batatas Nutrition 0.000 description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 4
- 240000000249 Morus alba Species 0.000 description 4
- 235000008708 Morus alba Nutrition 0.000 description 4
- 240000002948 Ophiopogon intermedius Species 0.000 description 4
- 244000046146 Pueraria lobata Species 0.000 description 4
- 235000010575 Pueraria lobata Nutrition 0.000 description 4
- 241000405414 Rehmannia Species 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 244000178320 Vaccaria pyramidata Species 0.000 description 4
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 241000545442 Radix Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006025 fining agent Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 235000020097 white wine Nutrition 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a blood sugar reducing food series. The food series are characterized by mainly comprising the following raw material of cassia sophera powder in part by weight, cleaned and dried cassia sophera stems, leaves, flowers and seeds are pulverized to 350-500 meshes by an ultrafine pulverizer, and the powder is air-dried and disinfected to obtain the the cassia sophera powder. The cassia sophera seed powder is prepared into tablets, chewable tablets, chewable beans, dropping pills and oral liquids for reducing blood sugar. The development of the food series is mainly used for treating increasing number of extensive patients with hypertension, hyperlipemia and hyperglycemia. The biscuit is prepared from the cassia sophera powder as a main material by adding auxiliary materials for reducing blood sugar, blood pressure and blood fat as well as additives. The food series have the effects of lowering weight, reducing blood sugar of diabetics and reducing complications and belong to health-care food for diabetics.
Description
Technical field
The invention belongs to field of health care food, relate in particular to a kind of blood sugar reducing food series.
Background technology
Diabetes are a kind of common endocrine system diseases, the traditional Chinese medical science is referred to as " quenching one's thirst ", to raise because insulin in human body definitely or relatively lacks concentration of glucose in the blood caused, sugar is in a large number from discharging urine, and many drinks, diuresis, many foods and Body weight loss, the phenomenon of becoming thin appear, in a single day diabetes are made a definite diagnosis and will be taken medicine all the life.
Diabetes are after cardiovascular and cerebrovascular diseases, malignant tumour, the 3rd killer of harm humans health.According to the statistics in 13 research centers such as the World Health Organization (WHO), IDF (IDF) and ADA (ADA), show, current global diabetic has reached 2.5 hundred million people, and wherein the patient of 20% (5,000 ten thousand) is in China.In China present stage, raising along with living standards of the people, food quality also improves greatly, but due to dietary structure and custom unreasonable and take exercise seldom, the number of suffering from diabetes sharply increases, the incidence of disease of diabetes in 1980 only has 1%, has 5% up till now, and the onset diabetes rate of economically developed Beijing, District of Shanghai has reached even respectively 8% and 11%.According to authoritative institution prediction, will reach 6,000 ten thousand people left and right to the diabetic of China in 2010.
At present, Western medicine be take as main in the antihypelipidemic product market of China, although the Western medicine effect is more obvious, the drug resistance that Long-term taking medicine causes, the resistance to the action of a drug, lesions of liver and kidney etc., allow the diabetic fully feel misery; And the general blood sugar reducing function of medicine, food of Chinese medicine hypoglycemic class is not obvious.Have investigation to show: the diabetic is to existing treatment, stabilizing blood sugar effect, urgent to the product demand that human body has no side effect again.
At present, the application of China's Chinese medicine has more and more obtained the approval of international community, its multiple medicinal material is evident in efficacy, various especially for the medicine of hypoglycemic, step-down, lipopenicillinase, but real evident in efficacy in practical application, only have several, such as gynostemma pentaphylla, cassia seed etc., and the application mentions obtaining cyperus boundless and indistinct (latin name Cassia sophera Linn), pulse family Caesalpinoidea Cassia, application seldom, is almost blank.The applicant finds that this Chinese medicine---cyperus is boundless and indistinct not only has remarkable result aspect hypoglycemic in actual production and application, in fat-reducing and step-down, significant curative effect is arranged too, and after especially adding the batching of certain proportional quantity, successful is strengthened.
Patented invention application CN1240115A and CN1562111A are just boundless and indistinct in hypoglycemic invention record to some extent to cyperus, and component is single, technique is simple, carries inconvenience, curative effect is not remarkable, therefore well do not promoted, wasted greatly this resource, on this basis, after the applicant has added a certain amount of food ingredient, in hypoglycemic, reach the effect of fat-reducing, step-down, and clinically be applied, obtained good economic benefit.
Summary of the invention
Blank in order to fill up application, the invention provides a kind of antihypelipidemic foodstuff of medicine-food two-purpose, the development of this series food mainly designs for vast " three height " patient in rising trend, and this food series is usingd the boundless and indistinct seed powder of cyperus and is made as major ingredient.The present invention is according to the Traditional Chinese Medicine tcm theory, and the raw material of employing integration of drinking and medicinal herbs is processed into through by scientific process, prescription and production technology science, reasonable; Be easy to take, evident in efficacy; Containing plant material is all that integration of drinking and medicinal herbs and process long-term practice are safety, stable, effective, facilitate the patient to use for a long time, have no side effect, be a kind of desirable product with blood sugar reducing function, food prepared therefrom, also can make medicine according to relevant laws and regulations as required.Concrete technical scheme of the present invention is as follows:
A kind of blood sugar reducing food series, it is characterized in that this food series is mainly to be made by the raw material of following weight portion: the boundless and indistinct cauline leaf of the cyperus after cleaning up and drying, flower and the boundless and indistinct seed of cyperus are crushed to 350～500 orders through micronizer, then dry, the boundless and indistinct powder of the sterilizing cyperus obtained.
Further, described blood sugar reducing food series, preparation: tablet, chewable tablets, chew beans, dripping pill, oral liquid for decreasing blood sugar, health liquor, nourishing jam.
Further, described blood sugar reducing food series, the boundless and indistinct cauline leaf of cyperus after cleaning up and drying, flower and the boundless and indistinct seed of cyperus are crushed to 350～500 orders through micronizer, then dry, sterilizing, adding 10 times of water gagings soaked 1 hour, after decocting 1 hour, taking liquid, then add 8 times of water gagings to decoct 1 hour taking liquid, merge twice and be concentrated into the crude drug concentration liquid of 1: 5, add again fining agent, cross 200 mesh sieves, standing 3-7 hour, mix, packing, sterilizing, obtain the described oral liquid for decreasing blood sugar of described diabetes medicine-food two-purpose product line.
Further, described blood sugar reducing food series, described oral liquid for decreasing blood sugar, its formula and preparation flow be first by tradition, concoct and breaking method process the boundless and indistinct seed powder of cyperus, the boundless and indistinct pollen of cyperus and dry after the boundless and indistinct cauline leaf powder of cyperus, then adopt research of super-pine crush equipment processing to pulverize; Make the grain diameter of the boundless and indistinct powder of the micron cyperus of pulverizing reach standby between 1～160 micron; Make again to contain 1-55g glucomannans powder, 5～18g xylosic alcohol powder in every 100CC oral liquid for decreasing blood sugar of processing; Its raw material sum is 100% ratio; After in above 72g raw material, first adding 90CC distilled water again; After fully stirring and evenly mixing, filter, again distilled water is added to 100CC in the stoste after filtration; Finally get the stoste embedding, irradiation sterilization, after check, packed products.
Further, described blood sugar reducing food series, described oral liquid for decreasing blood sugar comprises the boundless and indistinct powder of cyperus, the seed of cowherb, the Radix Astragali, Chinese yam, the dried rhizome of rehmannia, the fruit of Chinese magnoliavine, the tuber of dwarf lilyturf, dark plum, sealwort, matrimony vine, the root of kudzu vine, mulberry leaf, water, it is characterized in that the portion rate of preparing is comprised of 100 parts, 40 parts, the boundless and indistinct powder of cyperus, 5 parts of the seeds of cowherb, 3 parts of the Radixs Astragali, 2 parts of Chinese yams, 2 parts, the dried rhizome of rehmannia, 2 parts, the fruit of Chinese magnoliavine, 1 part of the tuber of dwarf lilyturf, 1 part of dark plum, 1 part of sealwort, 1.5 parts of matrimony vines, 1 part of the root of kudzu vine, 1 part, mulberry leaf, water.
Further, described blood sugar reducing food series, with the boundless and indistinct cauline leaf of cyperus after cleaning up and drying, it is raw material that flower and the boundless and indistinct seed of cyperus are crushed to through micronizer the boundless and indistinct powder of cyperus that 350～500 orders obtain, with 1% hydrochloric acid water solvent refluxing heating, boiled 2 hours to obtain extract, extract is extremely neutral by equivalent NaOH acid adjustment basicity, be concentrated into dry, standing after the thick paste thermosol, precipitate leaches, filtrate is used the extracted with diethyl ether secondary, reclaim ether, residue with before leach thing and merge, washing, ethyl alcohol recrystallization once, be pressed into various irregular tablets, dripping pill, chewable tablets, chew beans.
Further, described blood sugar reducing food series, take the boundless and indistinct cauline leaf of cyperus after cleaning up and drying and the boundless and indistinct seed of cyperus is crushed to through micronizer the boundless and indistinct powder of cyperus that 350～500 orders obtain and is raw material, with alcohol reflux, extract three times, extract is condensed into medicinal extract and obtains extract, in medicinal extract, adds proper amount of edible starch to not sticking, 95% alcohol granulation, 62～72 ℃ of dryings, be pressed into various irregular tablets, dripping pill, chewable tablets, chew beans.
Further, described health liquor is the boundless and indistinct seed 30g of cyperus, Chinese yam 15～30g, the fruit of Chinese magnoliavine 5～10g, rhizoma Gastrodiae 5～10 grams, and the leaching liquid that adds 5000g white wine is made.
Further, described nourishing jam is with by weight 10～20 portions of matrimony vines, 30～50 parts of boundless and indistinct powder of described cyperus, and 20 parts of honey and 10 parts of white sugar are that raw material is made.
The present invention also can be made into capsule, tea in bag, tablet, pill, also can be made into the detailed catalogue powder sticks with paste the formulations such as Instant Drinks tea, medicine materical crude slice,
Above-mentioned Chinese medicinal ingredients is through checking for many years, record and test gained, although their effect is different, but choosing of each Chinese medicine is not to be arbitrarily, the applicant is according to the proportioning of for many years each composition of test gained, be not by the raw material effect simple superposition of each composition, because may have interpromoting relation in five elements between various Chinese medicine materials, mutual reinforcement between, the multiple interactively such as mutual restraint between two drugs or the mutual-detoxication, and the applicant has selected above-mentioned raw materials accordingly according to this principle exactly, and determined the best proportioning between them, obtained the approval of clinical testing therefore, the application has significant meaning.
Beneficial effect:
The biscuit the present invention relates to shows through the security toxicology test: LD50 is 10000mg/kg, and Toxicological evaluation is nontoxic level, has no side effect.
One, the present invention is without any toxicity:
1, raw material sources of the present invention in the integration of drinking and medicinal herbs natural plants, through traditional Chinese medical science long-term clinical practice and numerous people, use for a long time proof, long-term taking has no side effect.
2, through toxicologic study, show nontoxicity of the present invention
1) acute toxicity test
Above-mentioned laboratory sample is made to suspension after crushed, to the mouse stomach administration, at viewing duration, do not find that animal has any toxic reaction with the dosage that is equivalent to 400 times of clinical daily dosage.Administration was observed in 14 days, none animal dead; After sacrifice of animal, dissect, its internal organs are observed Non Apparent Abnormality.Experiment shows, gastric infusion does not measure median lethal dose of the present invention, and zooperal dosis tolerata is 305 times of the maximum dose of clinical per day for adults.
2) long-term toxicity test for animals
By above-mentioned sample, with 5 times, 15 times, 75 times of clinical daily dosage, give rat long term administration in 6 months, the general activity after the large raticide of two dosage groups, the state of mind, hair, ight soil etc. are showed no obvious abnormalities; Peripheral hemogram before and after administration, comprise that red blood cell, platelet, hemoglobin, packed cell volume all fluctuate in normal range (NR); Liver, renal function index are showed no to obvious impact; During off-test in animal blood serum the content of total protein, albumin, alkaline phosphatase with control group, compare no significant difference; The electrograph inspection is all no abnormal; Each main organs visual inspection has no the morphological changes of various tissue components such as obvious enlargement, hyperemia, necrosis; The weight coefficient of the heart, liver, spleen, lung, kidney, thymus gland, adrenal gland, uterus, testis is compared without significant difference with control group; Histopathologic examination is showed no extremely.These results suggest that the present invention is safer, in trial dosage range without obvious toxic-side effects.
Two, Pharmacodynamics experiment:
Above-mentioned sample is measured to the administration of two dosage groups with 38 times, 10 times of clinical daily dosage, with the positive control group of Jiangtangwan pill, the water of take is model group, animal used as test is divided into to four experimental group at random, investigates blood glucose in diabetic rats due to alloxan, the impact of insulin level and the effect of β cell, result shows, high and low dose group of the present invention all had obvious hypoglycemic activity in 7,14 days in administration, P difference<0.01,<0.05, significant difference is arranged, its effect is better than Jiangtangwan pill.
Three, clinical practice
1. research object
Diabetic: treatment group 62 examples, 45 years old～67 years old age; Control group 41 examples, 47～68 years old age.
2. instructions of taking and the course for the treatment of
Of the present invention group: adopt the boundless and indistinct cauline leaf of cyperus, flower and the boundless and indistinct seed of cyperus after cleaning up and drying to be crushed to 350～500 orders through micronizer, then the capsule of dry, the boundless and indistinct powder of the sterilizing cyperus obtained being made, each serving 4 tablets, every tablet amounts is 0.2g, day takes 2 times, and each month is a course for the treatment of;
(Jiangtangwan pill group): each serving 10 grams, take every day 3 times, each month is a course for the treatment of;
3. result: the efficient of hypoglycemic of the present invention is 95.2%, than control group Jiangtangwan pill 90.2%, is high, in Table 1.
The clinical observation of table 1 adjuvant therapy of diabetes of the present invention
| Group | Case load | Produce effects | Effectively | Invalid | Efficient |
| The present invention | 62 | 25 | 35 | 2 | 95.2％ |
| Control group | 41 | 16 | 21 | 4 | 90.2％ |
Case 1
The Wang, the man, 65 years old, suffered from diabetes 7 years, take for a long time the treatment of Western medicine antidiabetic drug, " more than three " symptom is not obvious.Edema of lower extremity repeatedly occurs in this year, frequently, amount is few unfavorable for difficulty in walking very, enuresis nocturna, and the companion sees aversion to cold and cold limbs, shortness of breath and fatigue, lassitude, say less indifferent, soreness of waist and knee, receive food still can, light red, thin white, the deep,thready and forceless pulse of tongue of indented tongue margin, tongue nature.Blood pressure: 130/80mmHg, laboratory examination: urine albumen (+++), twenty-four-hour urine protein quantification 4.8g, blood urea nitrogen 6.50mmol/L, serum creatinine 180 μ mmol/L, T-CHOL 7.50mmol/L, fasting blood-glucose 8.9mmol/L, total serum protein 70.2mmol/L, albumin 40.4mmol/L, be diagnosed as diabetes B complication with diabetes ephrosis, distinguish as yin-yang deficiency, the syndrome of blood stasis due to qi deficiency of holding concurrently.Oral capsule of the present invention is after 20 days, and all diseases are namely seen obvious improvement.Check urine albumen (+), blood sugar 6.8mmol/L, serum creatinine 130 μ mol/L.
Case 2
Thank certain, the man, 60 years old, suffered from diabetes 8 years, weak, the burnout in the whole body is shown in first visit, being irritable and getting angry easily, honey stomach, eats and easily hungry more, and thirsty many drinks are drunk and easily thirsty more, dry and hard excrement, the red rolling and rapid pulse of tongue.Check: fasting blood-glucose 8.5mmol/L, glucose in urine (+++), oral capsule of the present invention,, every day 2 times, take thirsty alleviating on the 7th by each 4; Continuing to take medicine, it is normal to defecate in 15th, and it is strong that the whole body begins to feel, checks blood sugar 6.5mmol/L, glucose in urine (+); The adjusting that is careful in one's diet, continued to take 30, and blood sugar, glucose in urine all are down to normally, rear long-term taking, stable disease.
Separately an old community, do bulk testing, choose 120 people, through human experiment, morning, noon and afternoon every day each 3 times, each 2.Obesity (with high fat of blood), hypertension, hyperglycaemia symptom patient are arranged in 120 people, and everyone drinks 30-60 days, and drug withdrawal 30-60 days.Obesity patient's (with high fat of blood symptom) 40 people wherein, through check fasting plasma lipid, T-CHOL CT, triglyceride TG and HDL HDL, contrast test before and after drinking, carry out curative effect relatively: test was drunk 30 days again, experimenter TC, TG significantly descend, HDL obviously rises, and TC descends respectively 33.6%, 48.8%, 57.6%;
Wherein 40 hypertension symptom persons, ate after 30 days, obtains simultaneously good blood pressure lowering effect, and mean blood pressure descends 30%, the blood pressure drops amplitude: systolic pressure decline 3.14kpa, and diastolic pressure decline 2.83%kpa, its hypotensive effect is remarkable;
40 hyperglycemic patients are also obtained to good hypoglycemic, lipid-lowering effect; The experimenter is edible after 30 days, the TC 1.15mmol/L that on average descends, HDL rising 0.85mmol/L, the effect of TC and rising HDL wherein obviously descends, its effect is higher than vitamin E, the average rate of decrease that plays its glucose is 12.3%, and the average rate of decrease of fructosamine is to check its blood glucose value all to reach normal level after 21.2%, 30 day.Result of the test shows: the boundless and indistinct fat-reducing of the cyperus the present invention relates to, step-down, glucose-lowering biscuit are evident in efficacy.
Through pharmacological testing, show: have fragrant and sweet good to eat, fat-reducing defaecation, toxin expelling, produce refreshing effect to the mind, clear liver and improve vision, the effect of lipopenicillinase, step-down, hypoglycemic.The diseases such as obesity, coronary heart disease, hypertension, high fat of blood, DVT, cerebral hemorrhage, hemiplegia are had to obvious health-care efficacy.
The raw material of these series of products can take full advantage of the resource of artificial growth, and its raw material resources abundance is guaranteed, and production cost is low, efficiency is high, economic benefit, social benefit are remarkable.
Specific embodiment
Embodiment 1
A kind of blood sugar reducing food series, it is characterized in that this food series is mainly to be made by the raw material of following weight portion: the boundless and indistinct cauline leaf of the cyperus after cleaning up and drying, flower and the boundless and indistinct seed of cyperus are crushed to 350～500 orders through micronizer, then dry, the boundless and indistinct powder of the sterilizing cyperus obtained.
Further, described blood sugar reducing food series, preparation: tablet, chewable tablets, chew beans, dripping pill, oral liquid for decreasing blood sugar, health liquor, nourishing jam.
Further, described blood sugar reducing food series, the boundless and indistinct cauline leaf of cyperus after cleaning up and drying, flower and the boundless and indistinct seed of cyperus are crushed to 350～500 orders through micronizer, then dry, sterilizing, adding 10 times of water gagings soaked 1 hour, after decocting 1 hour, taking liquid, then add 8 times of water gagings to decoct 1 hour taking liquid, merge twice and be concentrated into the crude drug concentration liquid of 1: 5, add again fining agent, cross 200 mesh sieves, standing 3-7 hour, mix, packing, sterilizing, obtain the described oral liquid for decreasing blood sugar of described diabetes medicine-food two-purpose product line.
Further, described blood sugar reducing food series, described oral liquid for decreasing blood sugar, its formula and preparation flow be first by tradition, concoct and breaking method process the boundless and indistinct seed powder of cyperus, the boundless and indistinct pollen of cyperus and dry after the boundless and indistinct cauline leaf powder of cyperus, then adopt research of super-pine crush equipment processing to pulverize; Make the grain diameter of the boundless and indistinct powder of the micron cyperus of pulverizing reach standby between 1～160 micron; Make again to contain 1-55g glucomannans powder, 5～18g xylosic alcohol powder in every 100CC oral liquid for decreasing blood sugar of processing; Its raw material sum is 100% ratio; After in above 72g raw material, first adding 90CC distilled water again; After fully stirring and evenly mixing, filter, again distilled water is added to 100CC in the stoste after filtration; Finally get the stoste embedding, irradiation sterilization, after check, packed products.
Further, described blood sugar reducing food series, described oral liquid for decreasing blood sugar comprises the boundless and indistinct powder of cyperus, the seed of cowherb, the Radix Astragali, Chinese yam, the dried rhizome of rehmannia, the fruit of Chinese magnoliavine, the tuber of dwarf lilyturf, dark plum, sealwort, matrimony vine, the root of kudzu vine, mulberry leaf, water, it is characterized in that the portion rate of preparing is comprised of 100 parts, 40 parts, the boundless and indistinct powder of cyperus, 5 parts of the seeds of cowherb, 3 parts of the Radixs Astragali, 2 parts of Chinese yams, 2 parts, the dried rhizome of rehmannia, 2 parts, the fruit of Chinese magnoliavine, 1 part of the tuber of dwarf lilyturf, 1 part of dark plum, 1 part of sealwort, 1.5 parts of matrimony vines, 1 part of the root of kudzu vine, 1 part, mulberry leaf, water.
Further, described blood sugar reducing food series, with the boundless and indistinct cauline leaf of cyperus after cleaning up and drying, it is raw material that flower and the boundless and indistinct seed of cyperus are crushed to through micronizer the boundless and indistinct powder of cyperus that 350～500 orders obtain, with 1% hydrochloric acid water solvent refluxing heating, boiled 2 hours to obtain extract, extract is extremely neutral by equivalent NaOH acid adjustment basicity, be concentrated into dry, standing after the thick paste thermosol, precipitate leaches, filtrate is used the extracted with diethyl ether secondary, reclaim ether, residue with before leach thing and merge, washing, ethyl alcohol recrystallization once, be pressed into various irregular tablets, dripping pill, chewable tablets, chew beans.
Further, described blood sugar reducing food series, take the boundless and indistinct cauline leaf of cyperus after cleaning up and drying and the boundless and indistinct seed of cyperus is crushed to through micronizer the boundless and indistinct powder of cyperus that 350～500 orders obtain and is raw material, with alcohol reflux, extract three times, extract is condensed into medicinal extract and obtains extract, in medicinal extract, adds proper amount of edible starch to not sticking, 95% alcohol granulation, 62～72 ℃ of dryings, be pressed into various irregular tablets, dripping pill, chewable tablets, chew beans.The present invention can be made into capsule, tea in bag, tablet, pill, also can be made into the detailed catalogue powder sticks with paste the formulations such as Instant Drinks tea, medicine materical crude slice.
Further, described health liquor is the boundless and indistinct seed 30g of cyperus, Chinese yam 15～30g, the fruit of Chinese magnoliavine 5～10g, rhizoma Gastrodiae 5～10 grams, and the leaching liquid that adds 5000g white wine is made.
Further, described nourishing jam is with by weight 10～20 portions of matrimony vines, 30～50 parts of boundless and indistinct powder of described cyperus, and 20 parts of honey and 10 parts of white sugar are that raw material is made.
Finally it should be noted that: above embodiment only, in order to technical scheme of the present invention to be described, is not intended to limit; Although with reference to previous embodiment, the present invention is had been described in detail, those of ordinary skill in the art is to be understood that: it still can be modified to the technical scheme that aforementioned each embodiment puts down in writing, or part technical characterictic wherein is equal to replacement; And these modifications or replacement do not make the essence of appropriate technical solution break away from the spirit and scope of various embodiments of the present invention technical scheme.
Claims (1)
1. hypoglycemic nutrition jam is characterized in that: described nourishing jam is with by weight 10～20 portions of matrimony vines, 30～50 parts of boundless and indistinct powder of described cyperus, and 20 parts of honey and 10 parts of white sugar are that raw material is made; 30～50 parts of boundless and indistinct powder of described cyperus are that the boundless and indistinct cauline leaf of cyperus, flower and the boundless and indistinct seed of cyperus after cleaning up and drying is crushed to the 350-500 order through micronizer, then dry, the boundless and indistinct powder of the sterilizing cyperus obtained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100716370A CN102551065B (en) | 2012-03-19 | 2012-03-19 | Blood sugar reducing food series |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100716370A CN102551065B (en) | 2012-03-19 | 2012-03-19 | Blood sugar reducing food series |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102551065A CN102551065A (en) | 2012-07-11 |
| CN102551065B true CN102551065B (en) | 2013-11-27 |
Family
ID=46398712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100716370A Expired - Fee Related CN102551065B (en) | 2012-03-19 | 2012-03-19 | Blood sugar reducing food series |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102551065B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103039979A (en) * | 2012-11-24 | 2013-04-17 | 王凯莹 | Medicated diet namely yam and coix seed paste/beverage and preparation method thereof |
| CN103859378A (en) * | 2012-12-10 | 2014-06-18 | 天津红日药业股份有限公司 | Formula and preparation method of life cultivation and health preservation food helpful for reducing blood sugar |
| CN103239706B (en) * | 2013-05-13 | 2014-11-26 | 肖梅芬 | Earthworm protein for reducing blood glucose, improving microcirculation and eliminating diabetic complication and application thereof |
| CN103263660B (en) * | 2013-05-13 | 2015-05-20 | 肖梅芬 | Earthworm protein for reducing blood sugar and blood pressure and eliminating diabetic complications and application pf earthworm protein |
| CN105147983A (en) * | 2013-10-22 | 2015-12-16 | 南阳市食用菌技术交流中心（普通合伙） | Weight-losing health medicine |
| CN103976208B (en) * | 2014-04-14 | 2016-01-20 | 陆开云 | A kind of healthy jam and preparation method thereof |
| CN104522460A (en) * | 2014-11-27 | 2015-04-22 | 高铭鸿 | Jerusalem artichoke polysaccharide tablets beneficial for brain |
| CN105249331A (en) * | 2015-10-28 | 2016-01-20 | 张家界立功旅游农业发展有限公司 | Preparation method of blueberry fruit wine flavor chewable tablets and product thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100504C (en) * | 1999-05-18 | 2003-02-05 | 潘世全 | Cassia sophera hypoglycemic thirst-quenching beverage and productive process |
| CN1159994C (en) * | 2002-07-18 | 2004-08-04 | 潘世全 | Natural nutritive beverage and its preparing process |
| CN1330351C (en) * | 2003-07-30 | 2007-08-08 | 上海玉森新药开发有限公司 | Hypoglycemic oral liquid prepn and its production process |
| CN1562111A (en) * | 2004-03-19 | 2005-01-12 | 丰兴波 | Use of cassia sophera stem and leaf extract in preparing medicine for treating diabetes and improving its symptom |
| KR100736702B1 (en) * | 2005-01-04 | 2007-07-06 | 주식회사 하이폭시 | Composition comprising an extract of Cassia mimosoides var. nomame MAKINO for the prevention and treatment of ischemic diseases |
-
2012
- 2012-03-19 CN CN2012100716370A patent/CN102551065B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102551065A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102551065B (en) | Blood sugar reducing food series | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
| CN105079089A (en) | Preparation method of kudzuvine root and bitter gourd health-care food assisting in reducing blood glucose | |
| CN101879278B (en) | Medicine composition with hyperglycemic function, and preparation method and application thereof | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN105265985B (en) | A kind of corn stigma solid beverage and preparation method thereof | |
| CN102578668B (en) | Beverage for assisting in reducing blood sugar | |
| CN104398771B (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN105816505A (en) | Chinese herbal medicine compound preparation for treating diabetes and preparation and application of Chinese herbal medicine compound preparation | |
| CN105343585B (en) | A kind of corn stigma effervescent tablet and preparation method thereof | |
| EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
| CN102048215B (en) | Health beverage and preparation method thereof | |
| CN101147584B (en) | Health-care food capable of preventing and treating diabetes and preparation method thereof | |
| US20220047658A1 (en) | Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications | |
| CN101810649A (en) | Method for preparing pine needle distilled and concentrated solution | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN101336965A (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN100531783C (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| CN107260946A (en) | A kind of health-care edible capsule preparation method with auxiliary hyperglycemic function | |
| CN103720808B (en) | A kind of composition and use thereof, preparation method with relieving constipation effect | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN106421741A (en) | Water-soluble olive leaf extract health-care product and preparation method thereof | |
| CN102715502B (en) | Preparation method of health food with function of anti-diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131127 |